Device Firms Eye Rocketing Pay-For-Performance Insurance Plans Warily
This article was originally published in The Gray Sheet
Industry group AdvaMed says it is concerned a rapid shift toward pay-for performance and financial risk-sharing models by commercial insurers will discourage providers from giving patients newer devices and could stifle innovation.
You may also be interested in...
Keytruda is set to remain dominant despite knockback, though Tecentriq could claim prized NSCLC adjuvant approval first